

Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2020

<https://marketpublishers.com/r/P188C07F023EN.html>

Date: May 2020

Pages: 66

Price: US\$ 3,500.00 (Single User License)

ID: P188C07F023EN

Abstracts

Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype – Pipeline Review, H1 2020'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) – Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function.

The report 'Prostaglandin E2 Receptor EP4 Subtype – Pipeline Review, H1 2020' outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules

developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 7 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Immunology, Gastrointestinal, Respiratory, Women's Health and Genetic Disorders which include indications Colorectal Cancer, Gastric Cancer, Triple-Negative Breast Cancer (TNBC), Autoimmune Disorders, Endometriosis, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Pain, Rectal Cancer, Allergies, Asthma, Bladder Cancer, Bone Defects, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Esophageal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Inflammatory Pain, Knee Osteoarthritis, Liver Cancer, Lung Adenocarcinoma, Melanoma, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Osteoarthritis, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor, Transitional Cell Cancer (Urothelial Cell Cancer) and Ulcerative Colitis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Prostaglandin E2 Receptor EP4

Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects

The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -
Overview

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -
Companies Involved in Therapeutics Development

ARTham Therapeutics Inc

AskAt Inc

Eisai Co Ltd

GlaxoSmithKline Plc

Gurus BioPharm

Kaken Pharmaceutical Co Ltd

Mesentech Inc

NB Health Laboratory Co Ltd

Ono Pharmaceutical Co Ltd

RaQualia Pharma Inc

Rottapharm Biotech Srl

Shanghai Bioray Laboratory Inc

Sosei Heptares

Tempest Therapeutics Inc

Teon Therapeutics Inc

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug
Profiles

AAT-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARTEP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -

Dormant Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -

Discontinued Products

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) -

Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by ARTham Therapeutics Inc, H1 2020
Pipeline by AskAt Inc, H1 2020
Pipeline by Eisai Co Ltd, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Gurus BioPharm, H1 2020
Pipeline by Kaken Pharmaceutical Co Ltd, H1 2020
Pipeline by Mesentech Inc, H1 2020
Pipeline by NB Health Laboratory Co Ltd, H1 2020
Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Pipeline by RaQualia Pharma Inc, H1 2020
Pipeline by Rottapharm Biotech Srl, H1 2020
Pipeline by Shanghai Bioray Laboratory Inc, H1 2020
Pipeline by Sosei Heptares, H1 2020
Pipeline by Tempest Therapeutics Inc, H1 2020
Pipeline by Teon Therapeutics Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

ARTham Therapeutics Inc
AskAt Inc
Eisai Co Ltd
GlaxoSmithKline Plc
Gurus BioPharm
Kaken Pharmaceutical Co Ltd
Mesentech Inc
NB Health Laboratory Co Ltd
Ono Pharmaceutical Co Ltd
RaQualia Pharma Inc
Rottapharm Biotech Srl
Shanghai Bioray Laboratory Inc
Sosei Heptares
Tempest Therapeutics Inc
Teon Therapeutics Inc

I would like to order

Product name: Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/P188C07F023EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P188C07F023EN.html>